Introduction
Hematopoietic SCT (HSCT) is a potentially curative therapeutic procedure for patients with relapsed or refractory hematological malignancies. However, HSCT is associated with severe extra myeloid toxicity, resulting in significant morbidity and mortality. Among them, mucosal barrier injury (MBI) following intensive chemotherapy represents a major dose-limiting toxic effect that is often reported as the most debilitating symptom of patients undergoing HSCT. 1 MBI is a dynamic process that affects both the endothelial cells and the connective tissue and extends throughout the gastrointestinal system manifesting as oral, esophageal and intestinal mucositis. The symptoms of oral mucositis include difficulty in speaking, swallowing and alimentation and may be so severe to necessitate the use of opioid analgesics and total parenteral nutrition. 2 Intestinal mucositis is characterized by nausea, vomiting, abdominal pain and watery or bloody diarrhea and may accompany oral mucositis. Moreover, intestinal epithelial damage is probably associated with bacterial translocation into the bloodstream. 3 Patients with MBI, in general, have higher rates of severe complications such as infection, sepsis and hemorrhage. [4] [5] [6] [7] It is noteworthy that in the setting of allogeneic SCT intestinal epithelial damage is the key event in the vicious cycle of cytokine storm and the resultant alloreactive T-cell activation triggering the GVH effect. 8 Palifermin (Kepivance; Amgen Inc., Zug, Switzerland) is a recombinant human keratinocyte growth factor (KGF) first discovered in 1989. 9 An increasing proportion of studies have assessed the effectiveness of KGF on oral mucositis. Available data suggest that KGF reduces the incidence, severity and duration of oral mucositis, the use of analgesics and total parenteral nutrition without influencing engraftment. 10 Despite the encouraging data regarding the effectiveness of KGF on oral mucositis, there is a dearth of data regarding its activity on intestinal mucositis.
In the present study, we prospectively tested the efficacy of KGF in the prevention of intestinal mucositis in patients with various hematological malignancies treated with highdose chemotherapy and autologous HSCT (auto-SCT). 2 Â 2), respectively. The source of stem cells was mobilized with G-CSF, PBSCs in all but one patient. For one patient in group A, who was a poor mobilizer, BM harvesting under general anesthesia was performed after priming with G-CSF. Post transplantation, all patients received G-CSF 5 mg/kg from day þ 1 until neutrophil engraftment. Day of neutrophil (ANC) engraftment was defined as the first of 3 consecutive days with ANC40.5 Â 10 9 per liter. Day of platelet (PLT) engraftment was defined as the first of 3 consecutive days with PLT420 Â 10 9 per liter. The day of stem cell infusion was considered as day 0. All patients gave written informed consent.
Patients and methods

Patients
Study drug KGF was administered as follows: 60 mg/kg i.v. bolus daily Â 3 consecutive days. The third dose was infused at least 24 h before the start of the conditioning regimen. Three more consecutive daily doses of KGF 60 mg/kg were administered after the completion of conditioning regimen, starting on day 0 and until day þ 2.
Prevention and treatment of infections
All patients in both groups were hospitalized in single rooms and received pneumonocystis pneumonia prophylaxis with trimethoprime-sulfomethoxazole and acyclovir for HSV. No antimicrobial or antifungal prophylaxis was administered in our patients. Neutropenia was defined as ANCo0.5 Â 10 9 per liter or ANCo1.0 Â 10 9 per liter with a predicted decrease to ANCo0.5 Â 10 9 per liter during the next 3 days. Neutropenic fever was defined as a single oral temperature of X38.3 1C or a temperature of X38.0 1C for at least 1 h duration. 11 Patients with neutropenic fever received empirically broad-spectrum antibiotics (piperacillin-tazobactam with or without amikacin). Patients with persistent fever (more than 5 days) and/or pulmonary symptoms underwent high-resolution computed tomography (CT) of the lungs. Similarly patients with persisting fever underwent ultrasound and/or CT of the abdomen. Empirical antifungal treatment was administered to all patients with persistent fever, irrespectively of the results of radiological imaging studies. PCR or antigenemia monitoring for CMV reactivation was not routinely performed except in selected cases such as in patients with persistent fever and negative microbiological and radiological tests.
Video-capsule endoscopy studies
Three consecutive patients in group B and six patients in group A were scheduled for the video-capsule endoscopy (VCE) study on days þ 4 to þ 7, when they experienced the peak severity of abdominal symptoms. The day before the examination, they received only clear liquids diet-if they could maintain oral intake-and they fasted for 12 h until the examination, when they received early in the morning (0800-2000 hours) the capsule with a sip of water. We Table 1 Pretreatment clinical characteristics recorded VCE findings, VCE completion (in the cases that the capsule did not visualize the cecum, patients were followed clinically and with abdominal plain X-ray films daily until the capsules were retrieved in the feces) and VCE complications.
Oral and intestinal mucositis assessment
Patients were daily questioned about oral and intestinal mucositis-related symptoms. Physical examination and collection of data regarding the use of parenteral or transdermal analgesics, the frequency of bowel movements/nocturnal stools and the use of parenteral dehydration support were performed daily by the same investigators (PT and KG) from day 0 to day of hospital dismissal. The grade of oral mucositis was recorded according to WHO criteria. 12 Briefly, grading was as follows: grade 1, soreness/erythema; grade 2, soreness/ erythema plus ulcerations but able to eat solid foods; grade 3, as grade 2 but able to eat only liquid foods; grade 4, as grade 3 but unable to maintain oral intake (solid or liquid). The grade of intestinal mucositis was recorded according to National Cancer Institute Common Toxicity Criteria (NCI/ CTC) criteria. 13 Briefly, grading was as follows: grade 1, increase of less than four bowel movements per day without treatment, grade 2, 4-6 bowel movements or nocturnal stools; grade 3, seven or more bowel movements per day, or incontinence or need for parenteral support for dehydration and grade 4, requiring intensive care or hemodynamic collapse. The grade of abdominal pain was recorded according to NCI/CTC criteria. 13 Briefly, grading was as follows: grade 1, mild; grade 2, moderate and grade 3, severe, necessitating opioid analgesia.
Incidence of infections
The following data were collected for all patients: (1) episodes of neutropenic fever 11 without any documentation of infection, (2) episodes of neutropenic fever with positive blood cultures and (3) episodes of documented infections proven microbiologically or after radiological imaging.
End points
Oral and intestinal mucositis, incidence of neutropenic fever, incidence of documented infections (microbiologically or radiologically) and adverse events by day of hospital dismissal were the end points of our study.
Statistical analysis
Initially, the basic characteristics (disease, conditioning, previous mucositis and so on) were compared between the two groups. The adverse events of interest were peak oral mucositis grade, peak diarrhea grade, peak pain grade, incidence of neutropenic fever, incidence of positive blood cultures and incidence of microbiologically and/or radiologically documented infections. All the comparisons were two-sided and were made according to the Fisher's exact or w 2 -test with a level of significance less than 0.05. Also, logistic regression was used to find independent predictors of toxicity among the basic patient characteristics and palifermin treatment. All analyses were performed by using SPSS 11.0.
Results
Patient basic characteristics
In group A, there were more patients with multiple myeloma, whereas in group B the cases with Hodgkin's lymphoma or NHL were more frequent, although this difference was not statistically significant (P ¼ NS). In group B, more patients received treatment with the BEAM regimen in comparison with patients in group A, whereas more patients in group A received treatment with high-dose melphalan and these differences between the two groups were statistically significant (P ¼ 0.027). However, patients in group A were more heavily pretreated in comparison with patients in group B (P ¼ 0.026). Finally, the two groups did not differ significantly regarding all the other variables tested (Table 1) .
Engraftment
In group A, the median day of neutrophil engraftment was day þ 12, range (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , whereas the median day of PLT engraftment was day þ 14, range . In group B, the median day of neutrophil engraftment was day þ 11, range (9-28), whereas the median day of PLT engraftment was day þ 14, range (11-35). There were no statistically significant differences between the two groups (P ¼ NS).
Oral mucositis
In total, 3 out of 15 (20%) and 15 out of 20 (75%) patients developed grade 3 or more oral mucositis, in groups A and B, respectively. This difference was statistically significant (P ¼ 0.002; Table 2 ).
Intestinal mucositis
In total, 1 out of 15 (6.6%) and 13 out of 20 (65%) patients developed grade 3 or more intestinal mucositis (diarrhea) in groups A and B, respectively. This difference was also statistically significant (Po0.001). Similarly, significantly less patients in group A experienced moderate to severe abdominal pain in comparison with patients in group B (Po0.001; Table 2 ). Using multivariate analysis, we found that the statistical association between treatment with KGF use and lower incidence/severity of oral and intestinal mucositis was maintained even after adjustment for the variable that was significantly different between the two groups (difference in conditioning regimens; Table 3 ).
Video-capsule endoscopy
Group A. Our results were confirmed endoscopically. Six patients from group A underwent VCE. All patients on KGF treatment had normal VCE examinations (Figure 1) . Two of these patients have been reported in a previous study performed by our group. 14 Group B. VCE examination was performed in the last three consecutive patients from group B. In detail, one Palifermin, autologous SCT, prevention of mucositis P Tsirigotis et al patient had HD, whereas two patients had NHL and all were conditioned with the BEAM regimen. VCE examination revealed severe ulcerations and bleeding spots in the small intestine of all these three patients (Figure 2 ). These patients have been reported in a previous study performed by our group. 14 The procedure was uneventful in all the cases examined.
Incidence of fever, positive blood cultures and radiologically proven infections
In total, 11 out of 15 (73.3%) and 20 out of 20 (100%) patients developed neutropenic fever in groups A and B, respectively, and this difference was statistically significant (P ¼ 0.026). Positive blood cultures were observed in 3 out of 15 (20%), and 8 out of 20 (40%) patients in groups A and B, respectively (P ¼ 0.281; Table 2 ). X-ray and/or CT scanning of the lungs revealed the presence of pulmonary infiltrates in one and four patients of groups A and B, respectively. Radiological findings as well as microbiological examinations were not compatible with the diagnosis of fungal infection in any of these patients. However, all these patients were treated successfully with broad-spectrum antibiotics plus liposomal amphotericin-B. A female patient in group B developed CMV reactivation 40 days after transplantation manifested as persisting fever and a decline in blood counts. She was treated successfully with ganciclovir. No other infection was observed in any of our patients. PillCam TM SB - Figure 1 Normal small intestine mucosa.
Incidence of documented infections
In total 4 out of 15 (26.6%), and 11 out of 20 (55%), patients developed microbiologically (bloodstream) and/or radiologically (pulmonary) documented infection in groups A and B, respectively. The difference in the incidence of infections between the two groups was not statistically significant (P ¼ 0.167; Table 2 ).
Association between the degree of mucositis and the incidence of infections We evaluated the association between the severity of mucositis and the incidence of documented infections. For this purpose, we divided patients in two groups according to the degree of oral and intestinal mucositis, and irrespectively of treatment with KGF. Two out of fourteen (14.3%) patients with oral and/or intestinal mucositis grade 2 or less developed proven infection. On the contrary 13 out of 21 (61.9%) patients with oral and/or intestinal mucositis grade 3 or more developed proven infection, and this difference between the two cohorts of patients was statistically significant (P ¼ 0.006). Moreover, to evaluate the association of intestinal mucositis with the incidence of infections irrespectively of the presence of oral mucositis, we divided patients in two groups according to the degree of diarrhea and/or abdominal pain. Five out of twenty (25%) patients with diarrhea and/or abdominal pain grade 2 or less and 10 out of 15 (66.7%) patients with diarrhea and/or abdominal pain grade 3 or more developed proven infection, respectively, and again this difference was statistically significant (P ¼ 0.019; Table 4 ).
Safety of the study drug, and treatment-related mortality None of our patients developed any significant side effect attributable to the study drug except erythema, mild rash, pruritus, nasal congestion and low-grade fever. All these complications were easily manageable and resolved soon after the completion of treatment with KGF. No death related to treatment was observed in our study.
Discussion
KGF has shown promising activity in the prevention of mucositis in patients treated with high-dose chemoradiotherapy and auto-SCT. In a previous randomized controlled study performed by Spielberger et al. 15 , the authors tested the efficacy of KGF in patients conditioned with TBI and high-dose CY. In this study a significant reduction in the incidence and severity of oral mucositis was observed in the group of patients treated with KGF. Similar results have been reported in other studies in different groups of patients.
2,15-17 However, the efficacy of KGF in the prevention of intestinal mucositis was not examined in any of these previous studies. To our knowledge, our study is the first reporting on the efficacy of KGF in the prevention of intestinal mucositis in patients treated with SCT.
Mucosal toxicity is a known dose-limiting factor for all conditioning regimens used before transplantation. There is a limited amount of data regarding the incidence and severity of intestinal mucositis in patients treated with HSCT. 18 In the present study, the most commonly used conditioning regimens were high-dose melphalan and BEAM. It should be noticed that existing data suggest that both regimens are associated with high rates of mucosal toxicity. In a study reporting on the toxicity of high-dose melphalan in pediatric patients with solid tumors severe intestinal toxicity managed with i.v. opioids reached 40%. 19 Intestinal mucositis attributed to the BEAM regimen is a common side effect. Severe intestinal mucositis occurring after conditioning with BEAM ranges from 6 to 46%. [20] [21] [22] [23] However in the majority of studies, assessment of intestinal mucositis was not a primary objective. Moreover, authors used different staging criteria which make direct comparison an extremely difficult task. In addition in all of these studies abdominal pain, which along with diarrhea is a significant sign of intestinal mucositis, was not reported. 18 In our study, severe gastrointestinal mucositis was observed in 65% of patients in the control group.
Data from animal models 24, 25 showed that KGF treatment is effective in the prevention of intestinal mucositis. KGF is produced by mesenchymal cells and is a member of the fibroblast growth factor (FGF) superfamily. The gene in the jejunum and in the ileum of a patient who was not treated with palifermin. Based on the reported animal data and on the fact that KGF receptor is expressed in the whole of the intestinal epithelium, it is reasonable to suggest that KGF treatment might have an effect in the prevention of intestinal mucositis. Currently, efforts to assess intestinal barrier injury in humans are based on the measurement of certain biomarkers that reflect small intestine enterocyte mass such as citrulline. 27 In our study, we assessed small intestine injury by using VCE, which is a reliable, safe and objective method to evaluate gut damage in patients who underwent HSCT. 28 In our study, we observed a significant decrease in the incidence and severity of oral mucositis in patients treated with KGF. Moreover, a significant reduction in the incidence and severity of intestinal mucositis was observed as well. More importantly our results were confirmed endoscopically. In a previous study, using VCE performed by our group, we showed in a very small cohort of patients treated with auto-SCT that KGF reduces the severity and the incidence of intestinal mucositis.
14 In the present study four more patients underwent VCE examination. In summary, we observed: (1) VCE revealed the presence of severe ulcerations and bleeding lesions in all three consecutive patients not treated with KGF, whereas (2) VCE examination was normal in all six patients who received KGF.
Additionally, we observed a significant decrease in the incidence of febrile neutropenia in patients treated with KGF. Interestingly, we observed that patients with oral and/or intestinal mucositis grade 3 or more experienced significantly more infections, in comparison with the group of patients with oral and/or intestinal mucositis grade 2 or less. This finding is a further proof of the association between the degree of mucositis and the incidence of infections. Moreover, we analyzed the correlation between the degree of intestinal mucositis and the incidence of infections irrespectively of the severity of oral mucositis. Indeed, significantly less proven infections were observed in patients with intestinal mucositis grade 2 or less, in comparison with patients with more severe intestinal damage.
Our study has certain limitations. It is not randomized, and includes a rather small number of patients to make definite conclusions. However, using logistic regression, we showed that treatment with KGF remains a significant prognostic factor for the prevention of intestinal mucositis. Finally, we consider that these results seem promising, as this is the first study reporting on the efficacy of KGF in the prevention of intestinal mucositis. In view of the fact that severe mucositis and the resultant complications such as infections and inability to maintain oral intake represent significant complications of high-dose chemoradiotherapy, it is reasonable to assume that prevention of mucositis will result in the expansion of application of auto-SCT in medically unfit patients such as the elderly, or patients with significant comorbidities currently considered ineligible for a potentially curative therapeutic procedure. Large randomized trials are urgently needed to examine the efficacy of KGF in the prevention of intestinal mucositis and its impact on the incidence of infections in patients undergoing HSCT.
